Back

Antiarrhythmic effect of ranolazine in combination with selective NCX-inhibition in an experimental model of atrial fibrillation

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Atrial Fibrillation ePosters Rhythm Control, Antiarrhythmic Drugs ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Julian Wolfes

University Hospital of Munster, Munster (Germany)

172 More presentations in this session

Presentation thumbnail
Atrial fibrillation with or without structural abnormalities. Analysis from a nationwide database.
Doctor V. Mertz (FR)
Abstract Slides
Presentation thumbnail
Epicardial adipose tissue and atrial fibrillation: guilty as charged or guilty by association?
Doctor J. Sousa (Funchal, PT)
Abstract Slides
Presentation thumbnail
Timing and degree of left atrial stunning and reverse functional remodeling following electrical cardioversion in patients with recent onset atrial fibrillation
Doctor P. Arvanitis (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Irregular beat-to-beat hemodynamic properties determine left ventricular function during atrial fibrillation
Doctor A. Lyon (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
Mr M. Nazarzadeh (Oxford, GB)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources